Nanobiotix S.A. (NBTX)
$23.40-1.18%Close
SELLCRISIS · day 29
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $1.2B
- Beta
- 0.57
- P/E (TTM)
- -20.49
- Short % float
- 0.36%
- Days to cover
- 1.0
- SI change
- -16.6%
- 1W
- -6.77%
- 1M
- -36.77%
- vs SPY 1W
- -7.19%
- vs SPY 1M
- -38.83%
Industry peers
FMP comparable companies · ranked by market cap
- GHRSSELLGH Research PLC$1.5BCRISISQ 15$22.17-5.16%
- TYRASELLTyra Biosciences, Inc.$1.2BCRISISQ 5$20.93-1.71%
- SVRASELLSavara Inc.$980MRECOVERYQ 11$4.78-1.63%
- KURASELLKura Oncology, Inc.$943MBEARQ 12$10.62-1.89%
- ABUSSELLArbutus Biopharma Corp$923MCRISISQ 13$4.67-1.66%
- PROKSELLProKidney Corp.$531MRECOVERYQ 1$1.58-4.02%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on NBTX?
- LOPJLB’s latest quantitative signal on Nanobiotix S.A. (NBTX) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is NBTX in?
- Nanobiotix S.A. (NBTX) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Nanobiotix S.A. (NBTX) do?
- Nanobiotix S.A. is a clinical-stage biotechnology firm focused on developing innovative therapeutic solutions for cancer. The company's leading experimental drug, NBTXR3, is a sterile aqueous suspension comprising crystalline hafnium oxide nanoparticles. This treatment is currently undergoing development for its potential application in a broad spectrum of cancers, including soft tissue sarcoma…